SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature

go back to reference Amlashi SFA, Riffaud L, Brassier G, Morandi X (2003) Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 98(3):618–624. doi:10.1002/cncr.11537 CrossRefPubMed Amlashi SFA, Riffaud L, Brassier G, Morandi X (2003) Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 98(3):618–624. doi:10.​1002/​cncr.​11537 CrossRefPubMed

go back to reference Aylward EH, Habbak R, Warren AC, Pulsifer MB, Barta PE, Jerram M, Pearlson GD (1997) Cerebellar volume in adults with Down syndrome. Arch Neurol 54(2):209–212CrossRefPubMed Aylward EH, Habbak R, Warren AC, Pulsifer MB, Barta PE, Jerram M, Pearlson GD (1997) Cerebellar volume in adults with Down syndrome. Arch Neurol 54(2):209–212CrossRefPubMed

go back to reference Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S (2009) Down syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459(7250):1126–1130. doi:10.1038/nature08062 CrossRefPubMedPubMedCentral Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S (2009) Down syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459(7250):1126–1130. doi:10.​1038/​nature08062 CrossRefPubMedPubMedCentral

go back to reference Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH (2000) Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 9(2):195–202. doi:10.1093/hmg/9.2.195 CrossRefPubMed Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH (2000) Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 9(2):195–202. doi:10.​1093/​hmg/​9.​2.​195 CrossRefPubMed

go back to reference Benesch M, Moser A, Sovinz P, Lackner H, Schwinger W, Eder H, Urban C (2009) Medulloblastoma in a child with Down syndrome: long-term remission with multimodality treatment. Pediatr Blood Cancer 53(6):1150–1151. doi:10.1002/pbc.22109 CrossRefPubMed Benesch M, Moser A, Sovinz P, Lackner H, Schwinger W, Eder H, Urban C (2009) Medulloblastoma in a child with Down syndrome: long-term remission with multimodality treatment. Pediatr Blood Cancer 53(6):1150–1151. doi:10.​1002/​pbc.​22109 CrossRefPubMed

go back to reference Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachey PA (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297(5586):1559–1561. doi:10.1126/science.1073733 CrossRefPubMed Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachey PA (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297(5586):1559–1561. doi:10.​1126/​science.​1073733 CrossRefPubMed

go back to reference Costa AC (2011) On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci 33(5):414–427. doi:10.1159/000330861 CrossRefPubMedPubMedCentral Costa AC (2011) On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci 33(5):414–427. doi:10.​1159/​000330861 CrossRefPubMedPubMedCentral

go back to reference Das I, Park JM, Shin JH, Jeon SK, Lorenzi H, Linden DJ, Worley PF, Reeves RH (2013) Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci Transl Med 5(201):201ra120. doi:10.1126/scitranslmed.3005983 CrossRefPubMedPubMedCentral Das I, Park JM, Shin JH, Jeon SK, Lorenzi H, Linden DJ, Worley PF, Reeves RH (2013) Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci Transl Med 5(201):201ra120. doi:10.​1126/​scitranslmed.​3005983 CrossRefPubMedPubMedCentral

go back to reference Dlugosz AA, Talpaz M (2009) Following the hedgehog to new cancer therapies. N Engl J Med 361(12):1202–1205. doi:10.1056/NEJMe0906092 CrossRefPubMed Dlugosz AA, Talpaz M (2009) Following the hedgehog to new cancer therapies. N Engl J Med 361(12):1202–1205. doi:10.​1056/​NEJMe0906092 CrossRefPubMed

go back to reference Evans DG, Farndon PA, Burnell LD, Gattamaneni HR, Birch JM (1991) The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 64(5):959–961CrossRefPubMedPubMedCentral Evans DG, Farndon PA, Burnell LD, Gattamaneni HR, Birch JM (1991) The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 64(5):959–961CrossRefPubMedPubMedCentral

go back to reference Fabia J, Drolette M (1970) Malformations and leukemia in children with Down syndrome. Pediatrics 45(1):60–70PubMed Fabia J, Drolette M (1970) Malformations and leukemia in children with Down syndrome. Pediatrics 45(1):60–70PubMed

go back to reference Fujii K, Miyashita T (2014) Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review. Pediatr Int 56(5):667–674. doi:10.1111/ped.12461 CrossRefPubMed Fujii K, Miyashita T (2014) Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review. Pediatr Int 56(5):667–674. doi:10.​1111/​ped.​12461 CrossRefPubMed

go back to reference Fujii M, Noguchi K, Urade M, Muraki Y, Kishimoto H, Hashimoto-Tamaoki T, Nakano Y (2011) Novel PTCH1 mutations in Japanese nevoid basal cell carcinoma syndrome patients: two familial and three sporadic cases including the first Japanese patient with medulloblastoma. J Hum Genet 56(4):277–283. doi:10.1038/jhg.2011.2 CrossRefPubMed Fujii M, Noguchi K, Urade M, Muraki Y, Kishimoto H, Hashimoto-Tamaoki T, Nakano Y (2011) Novel PTCH1 mutations in Japanese nevoid basal cell carcinoma syndrome patients: two familial and three sporadic cases including the first Japanese patient with medulloblastoma. J Hum Genet 56(4):277–283. doi:10.​1038/​jhg.​2011.​2 CrossRefPubMed

go back to reference Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355(9199):165–169 Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355(9199):165–169

go back to reference Hasle H (2001) Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol 2(7):429–436CrossRefPubMed Hasle H (2001) Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol 2(7):429–436CrossRefPubMed

go back to reference Heretsch P, Tzagkaroulaki L, Giannis A (2010) Modulators of the hedgehog signaling pathway. Bioorg Med Chem 18(18):6613–6624. doi:10.1016/j.bmc.2010.07.038 CrossRefPubMed Heretsch P, Tzagkaroulaki L, Giannis A (2010) Modulators of the hedgehog signaling pathway. Bioorg Med Chem 18(18):6613–6624. doi:10.​1016/​j.​bmc.​2010.​07.​038 CrossRefPubMed

go back to reference Hori A, Walter GF, Haas J, Becker H (1992) Down syndrome complicated by brain tumors: case report and review of the literature. Brain Dev 14(6):396–400CrossRefPubMed Hori A, Walter GF, Haas J, Becker H (1992) Down syndrome complicated by brain tumors: case report and review of the literature. Brain Dev 14(6):396–400CrossRefPubMed

go back to reference Kieran MW (2014) Targeted treatment for sonic hedgehog-dependent medulloblastoma. Neuro-Oncology 16(8):1037–1047. doi:10.1093/neuonc/nou109 CrossRefPubMedPubMedCentral Kieran MW (2014) Targeted treatment for sonic hedgehog-dependent medulloblastoma. Neuro-Oncology 16(8):1037–1047. doi:10.​1093/​neuonc/​nou109 CrossRefPubMedPubMedCentral

go back to reference Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittman A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerencz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25(3):393–405. doi:10.1016/j.ccr.2014.02.004 CrossRefPubMedPubMedCentral Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittman A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerencz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25(3):393–405. doi:10.​1016/​j.​ccr.​2014.​02.​004 CrossRefPubMedPubMedCentral

go back to reference Liu H, Gu D, Xie J (2011) Clinical implications of hedgehog signaling pathway inhibitors. Chin J Cancer 30(1):13–26CrossRefPubMedPubMedCentral Liu H, Gu D, Xie J (2011) Clinical implications of hedgehog signaling pathway inhibitors. Chin J Cancer 30(1):13–26CrossRefPubMedPubMedCentral

go back to reference Narod SA, Stiller C, Lenoir GM (1991) An estimate of the heritable fraction of childhood cancer. Br J Cancer 63(6):993–999CrossRefPubMedPubMedCentral Narod SA, Stiller C, Lenoir GM (1991) An estimate of the heritable fraction of childhood cancer. Br J Cancer 63(6):993–999CrossRefPubMedPubMedCentral

go back to reference Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Pichter P, Taylor MD, Pfsiter SM (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12(12):818–834. doi:10.1038/nrc3410 CrossRefPubMedPubMedCentral Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Pichter P, Taylor MD, Pfsiter SM (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12(12):818–834. doi:10.​1038/​nrc3410 CrossRefPubMedPubMedCentral

go back to reference Olson JM, Hamilton A, Breslow NE (1995) Non-11p constitutional chromosome abnormalities in Wilms’ tumor patients. Med Pediatr Oncol 24(5):305–309CrossRefPubMed Olson JM, Hamilton A, Breslow NE (1995) Non-11p constitutional chromosome abnormalities in Wilms’ tumor patients. Med Pediatr Oncol 24(5):305–309CrossRefPubMed

go back to reference Paulino AC (2002) Current multimodality management of medulloblastoma. Curr Probl Cancer 26(6):317–356CrossRefPubMed Paulino AC (2002) Current multimodality management of medulloblastoma. Curr Probl Cancer 26(6):317–356CrossRefPubMed

go back to reference Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4(5):295–304. doi:10.1038/ncponc0794 CrossRefPubMed Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4(5):295–304. doi:10.​1038/​ncponc0794 CrossRefPubMed

go back to reference Rabin KR, Whitlock JA (2009) Malignancy in children with trisomy 21. Oncologist 14(2):164–173. doi:10.1634/theoncologist.2008-0217 CrossRefPubMedPubMedCentral Rabin KR, Whitlock JA (2009) Malignancy in children with trisomy 21. Oncologist 14(2):164–173. doi:10.​1634/​theoncologist.​2008-0217 CrossRefPubMedPubMedCentral

go back to reference Raz N, Torres IJ, Briggs SD, Spencer WD, Thornton AE, Loken WJ, Gunning FM, McQuain JD, Driesen NR, Acker JD (1995) Selective neuroanatomic abnormalities in Down’s syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 45(2):356–366CrossRefPubMed Raz N, Torres IJ, Briggs SD, Spencer WD, Thornton AE, Loken WJ, Gunning FM, McQuain JD, Driesen NR, Acker JD (1995) Selective neuroanatomic abnormalities in Down’s syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 45(2):356–366CrossRefPubMed

go back to reference Reynolds LE, Watson AR, Baker M, Jones TA, D’Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM (2010) Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome. Nature 465(7299):813–817. doi:10.1038/nature09106 CrossRefPubMedPubMedCentral Reynolds LE, Watson AR, Baker M, Jones TA, D’Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM (2010) Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome. Nature 465(7299):813–817. doi:10.​1038/​nature09106 CrossRefPubMedPubMedCentral

go back to reference Rickert CH, Göcke H, Paulus W (2002) Fetal ependymoma associated with Down’s syndrome. Acta Neuropathol 103(1):78–81CrossRefPubMed Rickert CH, Göcke H, Paulus W (2002) Fetal ependymoma associated with Down’s syndrome. Acta Neuropathol 103(1):78–81CrossRefPubMed

go back to reference Romer J, Curran T (2005) Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 65(12):4975–4978. doi:10.1158/0008-5472.CAN-05-0481 CrossRefPubMed Romer J, Curran T (2005) Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 65(12):4975–4978. doi:10.​1158/​0008-5472.​CAN-05-0481 CrossRefPubMed

go back to reference Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T (2004) Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 6(3):229–240. doi:10.1016/j.ccr.2004.08.019 CrossRefPubMed Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T (2004) Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 6(3):229–240. doi:10.​1016/​j.​ccr.​2004.​08.​019 CrossRefPubMed

go back to reference Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH (2006) Defective cerebellar response to mitogenic hedgehog signaling in Down [corrected] syndrome mice. Proc Natl Acad Sci U S A 103(5):1452–1456. doi:10.1073/pnas.0510750103 CrossRefPubMedPubMedCentral Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH (2006) Defective cerebellar response to mitogenic hedgehog signaling in Down [corrected] syndrome mice. Proc Natl Acad Sci U S A 103(5):1452–1456. doi:10.​1073/​pnas.​0510750103 CrossRefPubMedPubMedCentral

go back to reference Rubin LL, de Sauvage FJ (2006) Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 5(12):1026–1033. doi:10.1038/nrd2086 CrossRefPubMed Rubin LL, de Sauvage FJ (2006) Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 5(12):1026–1033. doi:10.​1038/​nrd2086 CrossRefPubMed

go back to reference Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre ML, Grill J (2010) Medulloblastoma in young children. Pediatr Blood Cancer 54(4):635–637. doi:10.1002/pbc.22372 CrossRefPubMed Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre ML, Grill J (2010) Medulloblastoma in young children. Pediatr Blood Cancer 54(4):635–637. doi:10.​1002/​pbc.​22372 CrossRefPubMed

go back to reference Ryeom S, Folkman J (2009) Role of endogenous angiogenesis inhibitors in Down syndrome. J Craniomaxillofac Surg 20(Suppl 1):595–596CrossRef Ryeom S, Folkman J (2009) Role of endogenous angiogenesis inhibitors in Down syndrome. J Craniomaxillofac Surg 20(Suppl 1):595–596CrossRef

go back to reference Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, Wick A, Witt O, Platten M, Herold-Mende C, Unterberg A, Pfister SM, Wick W, von Deimling A (2015) Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta neuropathologica. Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, Wick A, Witt O, Platten M, Herold-Mende C, Unterberg A, Pfister SM, Wick W, von Deimling A (2015) Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta neuropathologica.

go back to reference Satgé D (1996) A decreased incidence of neuroblastomas in Down’s syndrome and overproduction of S-100 b protein. Med Hypotheses 46(4):393–399. doi:10.1016/S0306-9877(96)90193-0 CrossRefPubMed Satgé D (1996) A decreased incidence of neuroblastomas in Down’s syndrome and overproduction of S-100 b protein. Med Hypotheses 46(4):393–399. doi:10.​1016/​S0306-9877(96)90193-0 CrossRefPubMed

go back to reference Satgé D, Monteil P, Sasco AJ, Vital A, Ohgaki H, Geneix A, Vekemans M, Réthoré MO (2001) Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing grade 2 astrocytoma. Cancer 91(8):1458–1466CrossRefPubMed Satgé D, Monteil P, Sasco AJ, Vital A, Ohgaki H, Geneix A, Vekemans M, Réthoré MO (2001) Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing grade 2 astrocytoma. Cancer 91(8):1458–1466CrossRefPubMed

go back to reference Satgé D, Rickert CH (2009) A medical enigma: persons with Down syndrome do not develop medulloblastoma. Neuroepidemiology 32(2):164. doi:10.1159/000184749 CrossRefPubMed Satgé D, Rickert CH (2009) A medical enigma: persons with Down syndrome do not develop medulloblastoma. Neuroepidemiology 32(2):164. doi:10.​1159/​000184749 CrossRefPubMed

go back to reference Satgé D, Sasco AJ, Carlsen NL, Stiller CA, Rubie H, Hero B, de Bernardi B, de Kraker J, Coze C, Kogner P, Langmark F, Hakvoort-Cammel FG, Beck D, von der Weid N, Parkes S, Hartmann O, Lippens RJ, Kamps WA, Sommelet D (1998) A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 58(3):448–452PubMed Satgé D, Sasco AJ, Carlsen NL, Stiller CA, Rubie H, Hero B, de Bernardi B, de Kraker J, Coze C, Kogner P, Langmark F, Hakvoort-Cammel FG, Beck D, von der Weid N, Parkes S, Hartmann O, Lippens RJ, Kamps WA, Sommelet D (1998) A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 58(3):448–452PubMed

go back to reference Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M (1998) A tumor profile in Down syndrome. Am J Med Genet 78(3):207–216CrossRefPubMed Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M (1998) A tumor profile in Down syndrome. Am J Med Genet 78(3):207–216CrossRefPubMed

go back to reference Satgé D, Stiller CA, Rutkowski S, von Bueren AO, Lacour B, Sommelet D, Nishi M, Massimino M, Garré ML, Moreno F, Hasle H, Jakab Z, Greenberg M, von der Weid N, Kuehni C, Zurriaga O, Vicente ML, Peris-Bonet R, Benesch M, Vekemans M, Sullivan SG, Rickert G (2013) A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. J Neuro-Oncol 112(1):107–114. doi:10.1007/s11060-012-1041-y CrossRef Satgé D, Stiller CA, Rutkowski S, von Bueren AO, Lacour B, Sommelet D, Nishi M, Massimino M, Garré ML, Moreno F, Hasle H, Jakab Z, Greenberg M, von der Weid N, Kuehni C, Zurriaga O, Vicente ML, Peris-Bonet R, Benesch M, Vekemans M, Sullivan SG, Rickert G (2013) A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. J Neuro-Oncol 112(1):107–114. doi:10.​1007/​s11060-012-1041-y CrossRef

go back to reference Slade I, Murray A, Hanks S, Kumar A, Walker L, Hargrave D, Douglas J, Stiller C, Izatt L, Rahman N (2011) Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Familial Cancer 10(2):337–342. doi:10.1007/s10689-010-9411-0 CrossRefPubMed Slade I, Murray A, Hanks S, Kumar A, Walker L, Hargrave D, Douglas J, Stiller C, Izatt L, Rahman N (2011) Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Familial Cancer 10(2):337–342. doi:10.​1007/​s10689-010-9411-0 CrossRefPubMed

go back to reference Smith MJ, Beetz C, Williams SG, Bhaskar SS, O’Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG (2014) Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32(36):4155–4161. doi:10.1200/JCO.2014.58.2569 CrossRefPubMed Smith MJ, Beetz C, Williams SG, Bhaskar SS, O’Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG (2014) Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32(36):4155–4161. doi:10.​1200/​JCO.​2014.​58.​2569 CrossRefPubMed

go back to reference Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH (2008) Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 451(7174):73–75. doi:10.1038/nature06446 Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH (2008) Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 451(7174):73–75. doi:10.​1038/​nature06446

go back to reference Thomas WD, Chen J, Gao YR, Cheung B, Koach J, Sekyere E, Norris MD, Haber M, Ellis T, Wainwright B, Marshall GM (2009) Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene 28(13):1605–1615. doi:10.1038/onc.2009.3 CrossRefPubMed Thomas WD, Chen J, Gao YR, Cheung B, Koach J, Sekyere E, Norris MD, Haber M, Ellis T, Wainwright B, Marshall GM (2009) Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene 28(13):1605–1615. doi:10.​1038/​onc.​2009.​3 CrossRefPubMed

go back to reference Threadgill DW (2008) Down’s syndrome: paradox of a tumour repressor. Nature 451(7174):21–22. doi:10.1038/451021a CrossRefPubMed Threadgill DW (2008) Down’s syndrome: paradox of a tumour repressor. Nature 451(7174):21–22. doi:10.​1038/​451021a CrossRefPubMed

go back to reference Trazzi S, Mitrugno VM, Valli E, Fuchs C, Rizzi S, Guidi S, Perini G, Bartesaghi R, Ciani E (2011) APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum Mol Genet 20(8):1560–1573. doi:10.1093/hmg/ddr033 CrossRefPubMed Trazzi S, Mitrugno VM, Valli E, Fuchs C, Rizzi S, Guidi S, Perini G, Bartesaghi R, Ciani E (2011) APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum Mol Genet 20(8):1560–1573. doi:10.​1093/​hmg/​ddr033 CrossRefPubMed

go back to reference Vaillant C, Monard D (2009) SHH pathway and cerebellar development. Cerebellum 8(3):291–301. doi:10.1007/s12311-009-0094-8 CrossRefPubMed Vaillant C, Monard D (2009) SHH pathway and cerebellar development. Cerebellum 8(3):291–301. doi:10.​1007/​s12311-009-0094-8 CrossRefPubMed

go back to reference Yang L, Xie G, Fan Q, Xie J (2010) Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29(4):469–481. doi:10.1038/onc.2009.392 CrossRefPubMed Yang L, Xie G, Fan Q, Xie J (2010) Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29(4):469–481. doi:10.​1038/​onc.​2009.​392 CrossRefPubMed